Why India should establish a vaccine injury compensation mechanism
Have sufficient facts. Writing the note now.
1. At a Glance
- India has no statutory or administrative no-fault compensation mechanism for persons suffering serious harm/death from vaccination, despite running the world's largest immunisation programmes [S4].
- The issue has crystallised into a constitutional question of Article 21 (right to life) obligations of the state towards citizens injured by state-promoted vaccination drives [S2][S4].
- The Supreme Court in Rachana Gangu & Anr. v. Union of India (2026 INSC 218) has directed the Union Government to frame such a policy — making this a live GS-II (polity/governance) and GS-III (health/science) crossover topic [S1][S4].
- Comparable schemes already exist in the UK, Australia, and Japan, giving India ready-made models to examine [S1].
2. Why in the News
- On 10 March 2026, the Supreme Court, in Rachana Gangu & Anr. v. Union of India & Ors. (2026 INSC 218), directed the Union Government (through the Ministry of Health and Family Welfare) to frame a "no-fault" compensation policy for serious adverse events following COVID-19 vaccination [S1][S2][S4].
- The case arose from a writ petition by parents of two young women who allegedly died after receiving their first dose of Covishield in 2021 [S1].
- The Bench (Justices Vikram Nath and Sandeep Mehta) held that India "does not appear to have in place any uniform or structured policy mechanism to provide redress to individuals who suffer adverse effects following vaccination" [S1][S2].
- The Court invoked comparative international practice (UK, Australia, Japan) to argue that swift, equitable, litigation-free relief is both feasible and necessary [S1].
3. Background & Evolution
- India's AEFI (Adverse Events Following Immunisation) surveillance system predates this controversy: India joined WHO's global AEFI post-marketing surveillance network by 2011 to monitor vaccine safety data, especially for newly introduced/prequalified vaccines [S3].
- In April 2017, WHO coordinated an India–Zimbabwe study assessing inter-rater reliability of the WHO AEFI causality-assessment methodology and software, indicating India's existing technical capacity for causality determination [S3].
- India's National AEFI Committee monitors and reports on adverse events; during COVID-19 vaccination it assessed that bleeding/clotting events were "minuscule" and consistent with baseline population rates [S5].
- Mass COVID-19 vaccination in India crossed 219.86 crore doses by late 2022, administered under a campaign that was, in practice, socially/institutionally mandated (workplace and institutional requirements), which the Court framed as a "social contract" between state and citizen [S4].
- Despite this scale and an existing AEFI monitoring apparatus, no parallel compensation apparatus was built — the gap the 2026 judgment seeks to close [S1][S2][S4].
4. Core Static Facts
| Item | Detail |
|---|---|
| Key case | Rachana Gangu & Anr. v. Union of India & Ors., 2026 INSC 218 [S1] |
| Bench | Justices Vikram Nath and Sandeep Mehta [S1] |
| Directed authority | Union Government / Ministry of Health and Family Welfare [S1] |
| Nature of policy directed | "No-fault" compensation policy (liability without proof of negligence) [S1][S2] |
| Constitutional hook | Article 21 — positive obligation of state during mass immunisation programmes [S2] |
| Trigger event | Deaths of two women allegedly post first dose of Covishield, 2021 [S1] |
| Existing monitoring body | National AEFI Committee (India) [S5] |
| International surveillance link | WHO global AEFI post-marketing surveillance network, India included by 2011 [S3] |
| Comparative models cited by SC | United Kingdom, Australia, Japan [S1] |
| Scale of programme | 219.86 crore COVID-19 vaccine doses administered by late 2022 [S4] |
5. Multi-Dimensional Analysis
Legal / Constitutional - Court held reliance on private tort suits creates inconsistent verdicts and unequal access to relief, potentially violating Article 14 (equality) [S1]. - Frames vaccine injury redress as flowing from Article 21, converting it from a policy choice into a justiciable state obligation [S2][S4]. - "No-fault" design removes the evidentiary burden of proving negligence — a deliberate departure from ordinary tort/consumer-protection remedies given the technical complexity of causality assessment [S1].
Governance / Ethical - The state actively promoted (and institutions effectively mandated) vaccination; the Court treats this as creating a reciprocal duty of care — "social contract" logic [S4]. - Absence of a mechanism is characterised as a "governance deficit" cutting to constitutional accountability [S4]. - Raises questions of transparency in causality assessment (who decides an event is vaccine-linked) — India already has WHO-aligned AEFI causality methodology to draw upon [S3].
Scientific / Technological - AEFI causality assessment is technically complex; WHO's revised classification system (2019 update) and India's participation in reliability studies (2017) provide a ready scientific backbone for any compensation scheme's determination process [S3]. - Serious adverse events are statistically rare; India's own data (bleeding/clotting post-COVID vaccination) showed rates in line with population baselines, underscoring that a compensation scheme addresses a narrow but real cohort [S5].
Administrative - Implementation will require the Health Ministry to design a scheme balancing speed (avoiding litigation delay) with fiscal predictability (avoiding open-ended liability) [S1]. - Coordination needed between the National AEFI Committee (causality determination) and a new compensation-disbursing authority [S5].
Comparative / International - UK, Australia, and Japan operate dedicated administrative vaccine-injury compensation programmes offering swift financial relief without requiring litigation — cited by the SC as workable precedents [S1].
6. Recent Developments (last 12-18 months)
- 10 March 2026: Supreme Court delivers judgment in Rachana Gangu v. Union of India (2026 INSC 218), directing the Centre to frame a no-fault compensation policy for serious COVID-19 vaccine adverse events [S1][S2].
- 17 April 2026: The Hindu publishes an opinion piece by Yashweer Singh arguing for institutionalising a permanent vaccine injury compensation mechanism, citing the judgment and India's 219.86-crore-dose COVID-19 campaign [S4].
- Ongoing: Union Government (Ministry of Health and Family Welfare) yet to notify the directed policy as of the article's publication [S1][S4].
7. Prelims Hooks
- The Supreme Court case on vaccine injury compensation is Rachana Gangu & Anr. v. Union of India & Ors., cited as 2026 INSC 218.
- The bench comprised Justices Vikram Nath and Sandeep Mehta.
- The Court directed a "no-fault" compensation policy — meaning compensation without requiring proof of negligence.
- The directed policy targets serious adverse events following COVID-19 vaccination (AEFI).
- The nodal ministry directed to act is the Ministry of Health and Family Welfare.
- The judgment grounds the state's obligation in Article 21 of the Constitution.
- India's monitoring body for vaccine adverse events is the National AEFI Committee.
- India joined WHO's global AEFI post-marketing surveillance network by 2011.
- WHO's AEFI causality assessment classification was updated in 2019 (2nd edition user manual).
- An India-Zimbabwe study (April 2017), coordinated by WHO, tested reliability of AEFI causality-assessment software.
- The Supreme Court cited UK, Australia, and Japan as countries with existing vaccine-injury compensation schemes.
- India administered 219.86 crore COVID-19 vaccine doses by late 2022.
- The petition originated from deaths of two women allegedly linked to the first dose of Covishield in 2021.
- The Court flagged possible violation of Article 14 if compensation were left to inconsistent private litigation.
8. Mains Relevance
- GS-II: Governance, Government policies for vulnerable sections, Welfare schemes; also Judiciary — structure, organisation, functioning; Separation of powers; Judicial activism/directions to executive.
- GS-III: Science & Technology — health, biotechnology; Issues related to public health infrastructure.
- Possible question stems: 1. "Discuss the constitutional basis for a state obligation to compensate victims of adverse events following immunisation. Refer to the Supreme Court's 2026 ruling in this context." (GS-II) 2. "Examine why India, despite decades of mass immunisation programmes, lacks a no-fault vaccine injury compensation mechanism. What lessons can it draw from comparable schemes abroad?" (GS-II/GS-III) 3. "'Judicial directions are increasingly filling policy vacuums in India's health governance.' Discuss with reference to recent Supreme Court interventions." (GS-II)
9. Related Topics to Study Next
- National AEFI Surveillance and Response System — the existing monitoring architecture this compensation scheme would plug into.
- Article 21 and expansion of right to life — line of SC judgments widening state positive obligations (health, environment, etc.).
- Universal Immunisation Programme (UIP) — India's broader vaccination delivery framework and scale.
- Vaccine liability/indemnity issues (Covishield/Covaxin) — legal disputes and manufacturer indemnity debates during COVID-19.
- Judicial activism vs separation of powers — recurring theme when courts direct executive policy-making.
- Comparative social security/compensation schemes (UK Vaccine Damage Payment, Japan/Australia models) — for comparative-governance answers.
- PM-JAY / public health financing architecture — relevant if compensation is funded through health budget mechanisms.
- Consumer Protection Act, 1986/2019 and medical negligence law — contrast with "no-fault" liability being proposed here.
10. Common Errors / Trap Areas
- Do not confuse AEFI surveillance/monitoring (which exists via the National AEFI Committee and WHO linkage since 2011) with AEFI compensation (which does NOT exist yet) — the case is about the latter's absence.
- Don't misattribute the directing ministry — it is the Ministry of Health and Family Welfare, not NITI Aayog or MoLJ.
- Avoid citing this as a "scheme already implemented" — as of the article (April 2026), it is a judicial direction to frame a policy, not an enacted compensation law.
- Don't conflate "no-fault" compensation with tortious/negligence-based compensation — no-fault removes the need to prove the vaccine manufacturer/state was negligent.
- Note the case name precisely: Rachana Gangu, not "Rachna Gupta" or similar — case-name garbling is a common recall error.
11. Sources
- [S1] SC Mandates No-Fault Vaccine Compensation Policy [2026] — https://blog.primelegal.in/supreme-court-covid-vaccine-compensation-policy-2026/ — (tier: 4)
- [S2] State Cannot Evade Compensation Responsibility For Vaccine-Related Deaths During Mass Immunisation Programme, Article 21 Imposes Positive Obligation: Supreme Court — https://24law.in/story/state-cannot-evade-compensation-responsibility-for-vaccine-related-deaths-during-mass-immunisation — (tier: 4)
- [S3] AEFI / Causality assessment resources — WHO — https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/aefi/aefi — (tier: 2)
- [S4] Why India should establish a vaccine injury compensation mechanism, Yashweer Singh, The Hindu, 17 April 2026 — https://www.thehindu.com/todays-paper/2026-04-17/th_international/articleGIJFS42E5-14267213.ece — (tier: 4)
- [S5] Bleeding and clotting events following COVID vaccination miniscule in India — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1719293 — (tier: 1)